# SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_DECISION_PLAN_001 Report

## 1. Artifact ID, status, base commit, and final verdict

| Field | Value |
|-------|-------|
| **Artifact ID** | `SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_DECISION_PLAN_001` |
| **Artifact type** | `scm_release_gate_decision_plan_metadata_only` |
| **Status** | `completed` |
| **Base commit** | `439f650` (Assemble SCM release gate review packet) |
| **Method family** | `SCM` — `production_candidate_gated` |
| **Recommended decision direction** | `defer_pending_empirical_validation` |
| **Planned closeout direction** | `closeout_as_reference_candidate` |
| **Portfolio handoff** | `handoff_to_method_portfolio` |
| **Final verdict** | `scm_release_gate_decision_plan_defined_defer_no_authorization_granted` |

This artifact is a **release-gate decision plan only**. It is **not a release-gate decision** and **not a release-gate approval**. **No production authorization was granted.**

---

## 2. Source-of-truth files audited

| File | Role |
|------|------|
| `SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_REVIEW_PACKET_001` | Assembled review packet (18 sections) |
| `SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_REVIEW_PLAN_001` | Domain/prerequisite review plan |
| `SCM_PRODUCTION_CANDIDATE_VALIDATION_IMPLEMENTATION_001` | Validation metadata scaffold |
| `SCM_PRODUCTION_CANDIDATE_NULL_CALIBRATION_IMPLEMENTATION_001` | Null calibration metadata scaffold |
| `SCM_PRODUCTION_CANDIDATE_JACKKNIFE_SENSITIVITY_IMPLEMENTATION_001` | Jackknife sensitivity metadata scaffold |
| `PRODUCTION_AUTHORIZATION_RELEASE_GATE_PLAN_001` | Cross-family release-gate model |
| Portfolio governance artifacts | AugSynth, TBRRidge, Bayesian TBR boundaries |

---

## 3. Prior-work reconciliation

| Prior artifact | Carried forward |
|----------------|-----------------|
| `SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_REVIEW_PACKET_001` | Packet inventory; blocked domains; followups |
| `SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_REVIEW_PLAN_001` | Review classifications and staged sequence |
| SCM evidence stack (validation/null/jackknife) | Metadata scaffolding only |
| `AUGSYNTH_REMEDIATION_AND_DIAGNOSTIC_VALIDATION_PLAN_001` | Next portfolio lane |
| `TBRRIDGE_INFERENCE_REMEDIATION_OR_RETIREMENT_AUDIT_001` | Later TBRRidge lane |
| `BAYESIAN_TBR_AND_TBR_RETIREMENT_BOUNDARY_AUDIT_001` | Later Bayesian TBR lane |

`prior_work_reconciled: true`. Packet assembly does **not** authorize production inference.

---

## 4. Decision-plan purpose and scope

This plan defines how a **future** `SCMReleaseGateDecision` artifact should evaluate the assembled SCM review packet. For the **current** evidence state, the recommended direction is conservative: **defer production authorization** and **hand off to the broader method portfolio**. SCM remains a governed reference candidate and validation baseline — not an approved production inference method.

---

## 5. Explicit non-goals

- No release-gate approval or decision execution
- No `approve_limited_production` for current evidence
- No SCM production inference, p-values, or causal CIs
- No selector/router production use
- No multicell SCM production claims
- No downstream integrations (TrustReport, CalibrationSignal, MMM, LLM, live API, scheduler, budget)
- No AugSynth/TBRRidge/Bayesian TBR production authorization
- No package-side agent authorization

---

## 6. Current SCM evidence packet summary

The review packet (`SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_REVIEW_PACKET_001`) inventories:

- Validation metadata scaffold (31 areas)
- Null calibration metadata scaffold (30 areas)
- Jackknife sensitivity metadata scaffold (37 areas)
- 15 release-gate domains — all blocked for authorization
- 15 evidence prerequisites — mostly `review_required` or `metadata_scaffold_present`

Packet status: `assembled_for_review`. No authorization granted.

---

## 7. Current SCM evidence limitations

1. All three evidence layers are **metadata scaffolding** — no SCM fitting, placebo computation, or jackknife refits
2. No empirical observed-panel validation results
3. No empirical null calibration or Type I error evidence
4. No empirical jackknife sensitivity results
5. Multicell validation lane incomplete
6. Selector shadow validation incomplete
7. Human governance review not completed
8. Statistical validation runtime absent across all layers

---

## 8. Planned decision options

| Option | Planned use for current evidence |
|--------|----------------------------------|
| `approve_limited_production` | **Not recommended** — insufficient empirical evidence |
| `approve_shadow_only` | Not recommended — metadata only |
| `defer_pending_empirical_validation` | **Recommended** |
| `reject_production_authorization` | Available but defer is preferred (preserves reference-candidate status) |
| `closeout_as_reference_candidate` | **Planned closeout direction** |
| `handoff_to_method_portfolio` | **Planned portfolio handoff** |

---

## 9. Recommended decision direction

**`defer_pending_empirical_validation`**

A future decision artifact should classify SCM as deferred/not approved for production inference unless real empirical validation evidence is added. SCM should not monopolize implementation attention.

---

## 10. Non-approval / defer rationale

- Evidence stack is metadata-only — contracts and registry rows, not empirical validation
- Null calibration metadata ≠ production p-values
- Jackknife sensitivity metadata ≠ causal CIs
- Multicell, selector, and downstream lanes remain blocked
- Portfolio has stronger or more flexible candidates requiring validation (AugSynth/ASCM first)
- SCM value is as governance reference and validation baseline, not production inference endpoint

---

## 11. Production inference authorization boundary

**Decision:** SCM production inference remains unauthorized. `scm_production_inference_authorized` stays false. `approve_limited_production` is not selected for current evidence.

---

## 12. Production p-value authorization boundary

**Decision:** SCM production p-values remain unauthorized. Empirical placebo/null calibration required before any future p-value consideration.

---

## 13. Causal CI authorization boundary

**Decision:** SCM causal confidence intervals remain unauthorized. Empirical jackknife sensitivity and causal uncertainty validation required before any future CI consideration.

---

## 14. Selector/router authorization boundary

**Decision:** Selector/router production use remains unauthorized. Shadow/non-authorizing consumption only.

---

## 15. Multicell/shared-control authorization boundary

**Decision:** Multicell/shared-control SCM production claims remain blocked pending separate validation lane.

---

## 16. Downstream authorization boundary

TrustReport, CalibrationSignal, MMM, LLM, live API, scheduler, budget optimization, and package-side agents remain unauthorized.

---

## 17. Required empirical evidence before any future approval

Future approval would require **all** of:

- `observed_panel_validation_results`
- `empirical_placebo_null_calibration_results`
- `jackknife_sensitivity_results`
- `donor_support_and_convex_hull_results`
- `pre_period_fit_and_trend_results`
- `failure_registry_review_results`
- `simulation_dgp_coverage_results`
- `assignment_design_validity_results`
- `multicell_dependence_multiplicity_results_where_applicable`
- `selector_shadow_validation_results_where_applicable`
- `human_governance_review_result`
- `rollback_revocation_expiration_policy`

Metadata scaffolding alone is insufficient.

---

## 18. Human governance review requirements

Human governance review remains required before any future approval: reviewers, review date, decision scope, evidence consulted, open investigations, backlog state, conditions, audit references.

---

## 19. Expiration/review-date/revocation requirements

Future decision must define `expiration_or_review_date` and `revocation_triggers`. Rollback policy must be in place before any scoped authorization.

---

## 20. Rollback/de-authorization requirements

Revocation triggers: validation regression, null FPR exceedance, jackknife instability, multicell violation, retire/replace violation, investigation escalation, governance revoke. No authorization exists to revoke today.

---

## 21. Method portfolio handoff rationale

SCM is valuable as a **governance reference lane** and validation baseline but should **not monopolize** implementation attention. Stronger or more flexible candidate methods need validation. Recommended handoff: **`handoff_to_method_portfolio`** after SCM closeout.

---

## 22. AugSynth/ASCM next-lane rationale

**AugSynth/ASCM** is the **first** portfolio target: stronger candidate due to residual correction, but requires residual-model governance and remediation validation (`AUGSYNTH_REMEDIATION_AND_DIAGNOSTIC_VALIDATION_PLAN_001`). **Not production-authorized.**

---

## 23. TBRRidge/Bayesian TBR later-lane rationale

- **TBRRidge:** practical geo diagnostic/restricted workhorse; inference validity and production-boundary validation remain unresolved (`TBRRIDGE_INFERENCE_REMEDIATION_OR_RETIREMENT_AUDIT_001`). **Not production-authorized.**
- **Bayesian TBR:** useful when governed priors exist; posterior intervals are not automatically causal CIs; prior compatibility must be governed (`BAYESIAN_TBR_AND_TBR_RETIREMENT_BOUNDARY_AUDIT_001`). **Not production-authorized.**

---

## 24. Closeout artifact plan

Next artifact: **`SCM_PRODUCTION_CANDIDATE_CLOSEOUT_AND_METHOD_PORTFOLIO_HANDOFF_001`** — execute SCM closeout as reference candidate and formalize portfolio handoff to AugSynth/ASCM (first), TBRRidge and Bayesian TBR (later). Not authorization.

---

## 25. Governance update strategy

Upon completion: add investigation `INV-SCM-PRODUCTION-CANDIDATE-RELEASE-GATE-DECISION-PLAN-001` (RESOLVED); add lane; set `next_artifact` to closeout/handoff artifact. Do not mark release gate approved or SCM production-authorized.

---

## 26. Future test strategy

Future closeout/handoff artifact tests should verify: defer direction preserved; closeout as reference candidate; portfolio handoff targets listed; no authorization flags true; AugSynth/TBRRidge/Bayesian TBR remain unauthorized.

---

## 27. Risks and ambiguities

- Decision plan may be misread as deferral approval — boundary language must be preserved
- SCM reference-candidate status may be confused with production candidacy
- Portfolio handoff sequencing requires explicit governance to avoid lane collision
- Empirical validation requirements are extensive — SCM may never reach production authorization without major new artifacts

---

## 28. Recommended next artifact

**`SCM_PRODUCTION_CANDIDATE_CLOSEOUT_AND_METHOD_PORTFOLIO_HANDOFF_001`**

---

## 29. Final verdict

**`scm_release_gate_decision_plan_defined_defer_no_authorization_granted`**

SCM release-gate decision plan is defined with conservative defer/handoff direction. SCM remains gated production-candidate. No release-gate approval, production inference, p-values, causal CIs, selector production use, multicell claims, downstream integrations, or portfolio method production authorization is granted. SCM closes as governed reference candidate; portfolio attention shifts to AugSynth/ASCM first.

---

| Summary | `docs/track_d/archives/SCM_PRODUCTION_CANDIDATE_RELEASE_GATE_DECISION_PLAN_001_summary.json` |
| Module | `panel_exp/validation/scm_production_candidate_release_gate_decision_plan_001.py` |
| Tests | `tests/validation/test_scm_production_candidate_release_gate_decision_plan_001.py` |
